Pharmosa Biopharm (ROCO:6875) Interest Expense: NT$-2.10 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
11 GF Score
Price NT$35.70
! 1 Warning Sign
View Full Analysis

What is Pharmosa Biopharm Interest Expense?

Pharmosa Biopharm ROCO:6875 +1.13% 11 Interest Expense is NT$-2.10 Mil as of Dec. 2025. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharmosa Biopharm's interest expense for the three months ended in Dec. 2025 was NT$ -0.50 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharmosa Biopharm's Operating Income for the three months ended in Dec. 2025 was NT$ -131.52 Mil. Pharmosa Biopharm's Interest Expense for the three months ended in Dec. 2025 was NT$ -0.50 Mil. Pharmosa Biopharm did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmosa Biopharm  (ROCO:6875) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmosa Biopharm's Interest Expense for the three months ended in Dec. 2025 was NT$-0.50 Mil. Its Operating Income for the three months ended in Dec. 2025 was NT$-131.52 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was NT$81.01 Mil.

Pharmosa Biopharm's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Pharmosa Biopharm did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Pharmosa Biopharm Interest Expense Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Interest Expense Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -1.21 -0.65 -2.86 -2.42 -2.10

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.55 -0.54 -0.52 -0.50
ROCO:6875
11GF Score
Pharmosa Biopharm Inc ROCO:6875
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-2.10 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Interest Expense of NT$-2.10 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharmosa Biopharm and its competitors.
Is Pharmosa Biopharm's Interest Expense too high?
Pharmosa Biopharm's current Interest Expense is NT$-2.10 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Interest Expense compare to VRTX and REGN?
Pharmosa Biopharm's Interest Expense of NT$-2.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Interest Expense is NT$-2.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current Interest Expense of NT$-2.10 Mil. The current Interest Expense is NT$-2.10 Mil. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Interest Expense is NT$-2.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score

Get the complete analysis for ROCO:6875

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.70
Price